NDLI: A novel solid dosage form of rifampicin and isoniazid with improved functionality

Content Provider	Springer Nature Link
Author	Gohel, Mukesh C. Sarvaiya, Krishnakant G.
Copyright Year	2007
Abstract	The aim of the present investigation was to develop a novel dosage form of rifampicin and isoniazid to minimize degradation of rifampicin in acidic medium and to modulate the release of rifampicin in the stomach and isoniazid in the intestine. Gastroretentive tablets of rifampicin (150 mg) were prepared by the wet granulation method using hydroxypropyl methylcellulose, calcium carbonate, and polyethylene glycol 4000. The granules and tablets of rifampicin were characterized. Hard gelatin capsules (size 4) containing a compacted mass of isoniazid (150 mg) and dicalcium phosphate (75 mg) were enteric coated. Two tablets of rifampicin and 1 capsule (size 4) of isoniazid were put into a hard gelatin capsule (size 00). The in vitro drug release and in vitro drug degradation studies were performed. Rifampicin was released over 4 hours by zero-order kinetics from the novel dosage form. More than 90% of isoniazid was released in alkaline medium in 30 minutes. The results of dissolution studies with the US Pharmacopeia XXIII method revealed that a substantial amount of rifampicin was degraded from the immediate release capsule containing rifampicin and isoniazid powder owing to drug accumulation in the dissolution vessel and also to the presence of isoniazid. The degradation of rifampicin to 3-formyl rifampicin SV (3FRSV) was arrested (3.6%–4.8% degradation of rifampicin at 4 hours) because of the minimization of physical contact between the 2 drugs and controlled release of rifampicin in acidic medium in the modified Rossett-Rice apparatus. This study concludes that the problem of rifampicin degradation can be alleviated to a certain extent by this novel dosage form.
Starting Page	E133
Ending Page	E139
File Format	PDF
Journal	AAPS PharmSciTech
Volume Number	8
Issue Number	3
e-ISSN	15309932
Language	English
Publisher	Springer-Verlag
Publisher Date	2007-01-01
Publisher Institution	American Association of Pharmaceutical Scientists
Publisher Place	New York
Access Restriction	One Nation One Subscription (ONOS)
Subject Keyword	Rifampicin gastroretentive isoniazid enteric dissolution degradation Biotechnology Biochemistry Pharmacy Pharmacology/Toxicology
Content Type	Text
Resource Type	Article

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Design and Evaluation of Novel Dosage Form of Rifampicin and Isoniazid with Improved Functionality

Controlled Release Hydrophilic Matrix Tablet Formulations of Isoniazid: Design and In Vitro Studies

Design and Evaluation of Novel Dosage Form of Rifampicin and Isoniazid with Improved Functionality

Protective Effects of Kaempferol on Isoniazid- and Rifampicin-Induced Hepatotoxicity

Improved Albendazole Dissolution Rate in Pluronic 188 Solid Dispersions

Improved dissolution of oleanolic acid with ternary solid dispersions

Enhancing and Sustaining AMG 009 Dissolution from a Bilayer Oral Solid Dosage Form via Microenvironmental pH Modulation and Supersaturation

Design and Evaluation of a Sustained Release Gastroretentive Dosage Form of Captopril: A Technical Note

QbD-Enabled Development of Novel Stimuli-Responsive Gastroretentive Systems of Acyclovir for Improved Patient Compliance and Biopharmaceutical Performance

A novel solid dosage form of rifampicin and isoniazid with improved functionality

Similar Documents

Design and Evaluation of Novel Dosage Form of Rifampicin and Isoniazid with Improved Functionality

Controlled Release Hydrophilic Matrix Tablet Formulations of Isoniazid: Design and In Vitro Studies

Design and Evaluation of Novel Dosage Form of Rifampicin and Isoniazid with Improved Functionality

Protective Effects of Kaempferol on Isoniazid- and Rifampicin-Induced Hepatotoxicity

Improved Albendazole Dissolution Rate in Pluronic 188 Solid Dispersions

Improved dissolution of oleanolic acid with ternary solid dispersions

Enhancing and Sustaining AMG 009 Dissolution from a Bilayer Oral Solid Dosage Form via Microenvironmental pH Modulation and Supersaturation

Design and Evaluation of a Sustained Release Gastroretentive Dosage Form of Captopril: A Technical Note

QbD-Enabled Development of Novel Stimuli-Responsive Gastroretentive Systems of Acyclovir for Improved Patient Compliance and Biopharmaceutical Performance

A novel solid dosage form of rifampicin and isoniazid with improved functionality